BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced the creation of new roles within its executive leadership team. Anne-Marie Law has been appointed to the newly created role of Chief Patient and Employee Experience Officer. Aradhana Sarin, M.D., has been appointed to the newly created role of Chief Strategy and Business Officer.
“We continue to evolve the organization to meet the needs of our growing business and stakeholder priorities,” said Ludwig Hantson, Ph.D., Chief Executive Officer at Alexion. “The creation of these two new roles underscores the importance of building the company to ensure long-term, sustainable future growth and the central role that patients play in everything we do at Alexion.”
Anne-Marie Law, Executive Vice President, Chief Patient and Employee
Ms. Law has served as Executive Vice President, Chief Human Resources Officer since joining Alexion in June 2017. Ms. Law is a human resources executive with more than 25 years of experience at global corporations with a strong track record of driving positive change and managing multi-national workforces in multiple global locations. In her new role, Ms. Law will focus on bringing together cross-functional and cross-geographical teams to fully understand the patient journey in order to turn patient insights into action and ensure that the company’s decisions are grounded in real-life insights. She will combine this with her continued leadership of the company’s human resources organization to cultivate world-class leadership and innovation capabilities, integrating learnings from stakeholders and improving the employee experience to, ultimately, elevate the patient experience.
“Anne-Marie has been critical in helping drive positive organizational change across Alexion and establishing an organization built on high performing, inclusive and aligned teams over the last year and a half,” said Dr. Hantson. “I am confident that in this new role, Anne-Marie will help ensure that our organization maintains its central focus on serving patients as the company continues to grow and evolve, while also increasing our capabilities and momentum in addressing patient needs.”
Aradhana Sarin, M.D., Executive Vice President, Chief Strategy and
Since joining Alexion in November 2017, Dr. Sarin has served as Senior Vice President, Business Development and Corporate Strategy. Dr. Sarin brings to Alexion more than 20 years of experience at global financial institutions with extensive knowledge of global healthcare systems as well as an excellent understanding of the biopharmaceutical sector and deep transactional experience. In her time at Alexion, Dr. Sarin has successfully led the company’s disciplined business development efforts, overseeing five business development deals that have been critical to rebuilding and diversifying Alexion’s pipeline. She has also been responsible for ensuring that the company is positioned to meet the strategic needs of its refocused corporate strategy. Reporting to Dr. Hantson, this new role will be responsible for overseeing the company’s corporate strategy, business development and business operations, including corporate planning.
“I am delighted to welcome Aradhana to our executive team. Her leadership and strategic vision have already had a transformative impact on the organization,” said Dr. Hantson. “This new role will be critical to ensuring continued growth and executional excellence across our increasingly complex and diverse portfolio as we work to achieve our Four Pillars of growth, building durable blockbuster franchises in PNH and atypical HUS, metabolics, neurology and FcRn.”
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS) and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG), and is also developing it for patients with neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition, the company is developing several mid-to-late-stage therapies, including a second complement inhibitor, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has been named to the Forbes list of the World’s Most Innovative Companies seven years in a row and is headquartered in Boston, Massachusetts’ Innovation District. The company also has offices around the globe and serves patients in more than 50 countries. This press release and further information about Alexion can be found at: www.alexion.com.
This press release contains forward-looking statements, including statements related to: the Company continues to evolve to meet the needs of its growing business and stakeholder priorities; the Company continues to grow and it is increasing capabilities and momentum in addressing patient needs; the Company is working to ensure continued growth and executional excellence across the increasingly complex and diverse portfolio; and the Company expects to achieve its Four Pillars of growth, building durable blockbuster franchises in PNH and atypical HUS, metabolics, neurology and FcRn. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ materially from those forward-looking statements, including for example: our dependence on sales from our principal product (SOLIRIS® (eculizumab)); our ability to facilitate the timely conversion of PNH patients (and any future indications) from SOLIRIS to ULTOMIRIS™ (ravulizumab-cwvz); payer, physician and patient acceptance of ULTOMIRIS as an alternative to SOLIRIS; appropriate pricing for ULTOMIRIS; our ability to grow revenues with sales due to our proposed blockbuster franchises; future competition from biosimilars and novel products; decisions of regulatory authorities regarding the adequacy of our research, marketing approval or material limitations on the marketing of our products; delays or failure of product candidates to obtain regulatory approval; delays or the inability to launch product candidates due to regulatory restrictions, anticipated expense or other matters; interruptions or failures in the manufacture and supply of our products and our product candidates; failure to satisfactorily address matters raised by the FDA and other regulatory agencies; results in early stage clinical trials may not be indicative of full results or results from later stage or larger clinical trials (or broader patient populations) and do not ensure regulatory approval; the possibility that results of clinical trials are not predictive of safety and efficacy and potency of our products (or we fail to adequately operate or manage our clinical trials) which could cause us to halt trials, delay or prevent us from making regulatory approval filings or result in denial of approval of our product candidates; unexpected delays in clinical trials; unexpected concerns that may arise from additional data or analysis obtained during clinical trials; future product improvements may not be realized due to expense or feasibility or other factors; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; inability to complete planned acquisitions due to failure of regulatory approval or material changes in target or otherwise; inability to complete acquisitions and investments due to increased competition for technology; the possibility that current rates of adoption of our products are not sustained; the adequacy of our pharmacovigilance and drug safety reporting processes; failure to protect and enforce our data, intellectual property and proprietary rights and the risks and uncertainties relating to intellectual property claims, lawsuits and challenges against us; the risk that third party payors (including governmental agencies) will not reimburse or continue to reimburse for the use of our products at acceptable rates or at all; failure to realize the benefits and potential of investments, collaborations, licenses and acquisitions; the possibility that expected tax benefits will not be realized; assessment of impact of recent accounting pronouncements; potential declines in sovereign credit ratings or sovereign defaults in countries where we sell our products; delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement; uncertainties surrounding legal proceedings, company investigations and government investigations, including investigations of Alexion by the U.S. Securities and Exchange Commission (SEC) and U.S. Department of Justice; the risk that estimates regarding the number of patients with PNH, aHUS, gMG, HPP and LAL-D and other future indications we are pursuing are inaccurate; the risks of changing foreign exchange rates; risks relating to the potential effects of the Company's restructuring; risks related to the acquisition of Syntimmune and other companies and co-development efforts; risks related to cybersecurity matters or unauthorized access to our computer networks; and a variety of other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Annual Report on Form 10-K for the year ended December 31, 2018 and in our other filings with the SEC. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.